Clinical and cytogenetic characteristics of patients achieving CR with tipifarnib plus etoposide
| Age, y/sex . | Prior SAML . | Prior treatment* . | PS† . | Comorbidities . | Cytogenetics . | Dose level . | DFS/OS, mo . |
|---|---|---|---|---|---|---|---|
| 85/F | Yes | 0 | 1 | Breast carcinoma, sinusitis, HBP | 46XX, 13q− | 2A | 32/37.5+ |
| 72/F | No | 0 | 1 | HBP, spinal stenosis | 46XX | 2A | 16/35+ |
| 83/F | Yes | 2 | 2 | NHL, diverticulitis, UTI | 45X,−X, t(1;11) iso8q, 20q− | 2B | 2.5/6 |
| 71/F | Yes | 2 | 1 | Breast carcinoma, osteoporosis | 46XX | 3A | 23/34+ |
| 71/M | Yes | 0 | 1 | HBP, osteoarthritis | 46XY | 3A | 9.6/23 |
| 85/F | No | 0 | 1 | None | 46XX | 3A | 9.9/12.8 |
| 83/F | Yes | 0 | 0 | HBP, hypothyroidism, arthritis | 46XX, 5q−,7q− 20q− | 4A | 6.7/9.5 |
| 76/F | No | 0 | 1 | Atrial fibrillation | 46XX | 4A | 19.1/22 |
| 81/M | Yes | 1 | 2 | Pneumonia, arthritis, HBP femoral DVT | 46XY | 4B | 8.1/11.2 |
| 76/F | No | 0 | 1 | Gastritis with ulcer, hypothyroidism | 46XX | 4B | 5.4/11 |
| 71/F | Yes | 1,2 | 1 | Breast carcinoma, gastric ulcer | 46XX | 5A | 2.8/4 |
| 77/M | Yes | 1 | 2 | Chronic renal failure, CAD pneumonia, asthmatic bronchitis | 46XY, 20q− | 5B | 4/6.6 |
| 77/F | Yes | 0 | 1 | HBP, hypothyroidism, rectal fissure | 46XX | 6A | 22.1+/24 |
| 77/F | Yes | 2 | 2 | Lung carcinoma, CAD, HBP, DM | 46XX, t(9;11;19) | 7A | 9.3/11.2 |
| 81/M | No | 0 | 2 | COPD, HBP, urosepsis | 47XY,+8 | 7B | 7.3/8.3 |
| 79/F | No | 0 | 1 | Colon carcinoma, HBP | 46XX | 8A | 20.7+/22+ |
| 76/M | No | 0 | 1 | Colon carcinoma, seizure disorder, CAD, DOE | 46XY, t(9;11) | 8A | 9.4/10.7 |
| 80/F | No | 0 | 0 | BP | 45XX, −7 | 8A | 20.5+/22+ |
| 72/F | Yes | 0 | 2 | DM, pneumonia, HBP, arthritis, essential tremor | 47XX,+1,+3q,−5Q,−7,−10,+12p, +17p,+21q | 9A | 8.8/17.2 |
| 76/F | Yes | 1,2 | 2 | Breast carcinoma, GERD, COPD, recurrent UTI | 46XX | 9A | 15.2/18.5+ |
| 79/M | Yes | 1 | 1 | HBP, gout, GERD, COPD | Not done | 9A | 9.7/19+ |
| Age, y/sex . | Prior SAML . | Prior treatment* . | PS† . | Comorbidities . | Cytogenetics . | Dose level . | DFS/OS, mo . |
|---|---|---|---|---|---|---|---|
| 85/F | Yes | 0 | 1 | Breast carcinoma, sinusitis, HBP | 46XX, 13q− | 2A | 32/37.5+ |
| 72/F | No | 0 | 1 | HBP, spinal stenosis | 46XX | 2A | 16/35+ |
| 83/F | Yes | 2 | 2 | NHL, diverticulitis, UTI | 45X,−X, t(1;11) iso8q, 20q− | 2B | 2.5/6 |
| 71/F | Yes | 2 | 1 | Breast carcinoma, osteoporosis | 46XX | 3A | 23/34+ |
| 71/M | Yes | 0 | 1 | HBP, osteoarthritis | 46XY | 3A | 9.6/23 |
| 85/F | No | 0 | 1 | None | 46XX | 3A | 9.9/12.8 |
| 83/F | Yes | 0 | 0 | HBP, hypothyroidism, arthritis | 46XX, 5q−,7q− 20q− | 4A | 6.7/9.5 |
| 76/F | No | 0 | 1 | Atrial fibrillation | 46XX | 4A | 19.1/22 |
| 81/M | Yes | 1 | 2 | Pneumonia, arthritis, HBP femoral DVT | 46XY | 4B | 8.1/11.2 |
| 76/F | No | 0 | 1 | Gastritis with ulcer, hypothyroidism | 46XX | 4B | 5.4/11 |
| 71/F | Yes | 1,2 | 1 | Breast carcinoma, gastric ulcer | 46XX | 5A | 2.8/4 |
| 77/M | Yes | 1 | 2 | Chronic renal failure, CAD pneumonia, asthmatic bronchitis | 46XY, 20q− | 5B | 4/6.6 |
| 77/F | Yes | 0 | 1 | HBP, hypothyroidism, rectal fissure | 46XX | 6A | 22.1+/24 |
| 77/F | Yes | 2 | 2 | Lung carcinoma, CAD, HBP, DM | 46XX, t(9;11;19) | 7A | 9.3/11.2 |
| 81/M | No | 0 | 2 | COPD, HBP, urosepsis | 47XY,+8 | 7B | 7.3/8.3 |
| 79/F | No | 0 | 1 | Colon carcinoma, HBP | 46XX | 8A | 20.7+/22+ |
| 76/M | No | 0 | 1 | Colon carcinoma, seizure disorder, CAD, DOE | 46XY, t(9;11) | 8A | 9.4/10.7 |
| 80/F | No | 0 | 0 | BP | 45XX, −7 | 8A | 20.5+/22+ |
| 72/F | Yes | 0 | 2 | DM, pneumonia, HBP, arthritis, essential tremor | 47XX,+1,+3q,−5Q,−7,−10,+12p, +17p,+21q | 9A | 8.8/17.2 |
| 76/F | Yes | 1,2 | 2 | Breast carcinoma, GERD, COPD, recurrent UTI | 46XX | 9A | 15.2/18.5+ |
| 79/M | Yes | 1 | 1 | HBP, gout, GERD, COPD | Not done | 9A | 9.7/19+ |
SAML indicates secondary AML; HBP, high blood pressure; NHL, non-Hodgkin lymphoma; UTI, urinary tract infection; DVT, deep vein thrombosis; CAD, coronary artery disease; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease; DOE, dyspnea on exertion; and GERD, gastroesophageal reflux disease.
Prior treatment: 0 indicates none; 1, antecedent hematologic disorder and 2, prior malignancy.
Performance status based on Eastern Cooperative Oncology Group criteria.